Company attributes
Other attributes
Kronos Bio is a company that is dedicated to the discovery and development of therapies which modulate historically undruggable targets. It is dedicated to the discovery and development of novel cancer therapeutics that are designed to revolutionalize patient outcomes by targeting dysregulated transcription.
The company leverages deep capabilities in high-throughput small molecule microarrays, targeted protein degradation, and cancer biology for identifying potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.
Its proprietary product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) through which they drive oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an investigational spleen tyrosine kinase (SYK) inhibitor that is being developed for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
